Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations

• Published in: Scandinavian journal of infectious diseases 2009, Vol.41 (6-7), p.389-402
• Main Authors: Lagging, Martin, Wejstål, Rune, Uhnoo, Ingrid, Gerdén, Barbro, Fischler, Björn, Friman, Styrbjörn, Josephson, Filip, Karlström, Olle, Sangfelt, Per, Schvarz, Robert, Weiland, Ola, For The Swedish Consensus Group
• Format: Article
• Language: English
• Subjects: Acute Disease; Adult; adverse effects; Antiviral Agents; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Biological and medical sciences; Child; Chronic; Dermatologi och venereologi; Dermatology and Venereal Diseases; drug therapy; Hepacivirus; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C virus; Hepatitis C, Chronic - drug therapy; Human viral diseases; Humans; Infectious Diseases; Infektionssjukdomar; Medical sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Ribavirin; Ribavirin - adverse effects; Ribavirin - therapeutic use; Sweden; therapeutic use; Viral diseases; Viral hepatitis
• ISSN: 0036-5548; 1651-1980; 1651-1980
• DOI: 10.1080/00365540902998271

In a recent expert meeting, Swedish recommendations for the treatment of HCV infection were upgraded. The panel recommends vaccination against both hepatitis A and B in patients with HCV. Therapy for symptomatic acute HCV infection should be initiated if spontaneous resolution has not occurred within 12 weeks, whereas asymptomatic acute HCV should be treated upon detection. Patients with genotype 2/3 infection should generally be treated for 24 weeks. In patients with a very rapid viral response (vRVR), i.e. HCV RNA below 1000 IU/ml on d 7, treatment can be shortened to 12-16 weeks, provided that no dose reduction has been made. For genotype 1 patients with rapid viral response (RVR), 24 weeks treatment is recommended. For patients with a complete early viral response (cEVR), 48 weeks treatment is recommended, whereas 72 weeks treatment should be considered for patients with partial early viral response (pEVR). For patients with difficult-to-treat disease and with pronounced anaemia, erythropoietin can be used to maintain the ribavirin dose. In HCV-HIV coinfected patients, combination therapy for HCV should, if possible, be initiated before anti-retroviral therapy (ART) is indicated. For liver transplant patients pre-emptive therapy is not recommended; hence, treatment should be deferred until histological recurrence.